Tumor endothelial cells (TEC) differ from the normal counterpart, in both gene expression and functionality. TEC may acquire drug resistance, a characteristic that is maintained in vitro. There is evidence that TEC are more resistant to chemotherapeutic drugs, substrates of ATP-binding cassette (ABC) transporters. TEC express p-glycoprotein (encoded by ABCB1), while no difference in other ABC transporters was revealed compared to normal endothelia. A class of tyrosine kinase inhibitors (TKI), used as angiostatic compounds, interferes with the ATPase activity of p-glycoprotein, thus impairing its functionality. The exposure of ovarian adenocarcinoma TEC to the TKIs sunitinib or sorafenib was found to abrogate resistance (proliferation and motility) to doxorubicin and paclitaxel in vitro, increasing intracellular drug accumulation. A similar effect has been reported by the p-glycoprotein inhibitor verapamil. No beneficial effect was observed in combination with cytotoxic drugs that are not p-glycoprotein substrates. The current paper reviews the mechanisms of TEC chemoresistance and shows the role of p-glycoprotein in mediating such resistance. Inhibition of p-glycoprotein by anti-angiogenic TKI might contribute to the beneficial effect of these small molecules, when combined with chemotherapy, in counteracting acquired drug resistance.
This is a preview of subscription content, log in to check access.
We are grateful to Sara Figini for technical support and to Viviana Rossi for assistance in manuscript preparation.
This study was supported by a Grant from the Italian Association for Cancer Research (AIRC No. 12182 and IG No. 18853 to RG).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
All applicable international, national and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with ethical standards of the institution or practice at which the studies were conducted.
McMillin DW, Negri JM, Mitsiades CS (2013) The role of tumour–stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12:217–228. doi:10.1038/nrd3870CrossRefPubMedGoogle Scholar
Huijbers EJM, van Beijnum JR, Thijssen VL et al (2016) Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 25:26–37. doi:10.1016/j.drup.2016.02.002Google Scholar
Alessandri G, Chirivi RG, Fiorentini S et al (1999) Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin Exp Metastas 17:655–662CrossRefGoogle Scholar
Bussolati B, Deregibus MC, Camussi G (2010) Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr Vasc Pharmacol 8:220–232CrossRefPubMedGoogle Scholar
Silini A, Ghilardi C, Figini S et al (2012) Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment. Cell Mol Life Sci CMLS 69:1167–1178. doi:10.1007/s00018-011-0862-8CrossRefPubMedGoogle Scholar
Bussolati B, Deambrosis I, Russo S et al (2003) Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J Off Publ Fed Am Soc Exp Biol 17:1159–1161. doi:10.1096/fj.02-0557fjeGoogle Scholar
Grange C, Bussolati B, Bruno S et al (2006) Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep 15:381–386PubMedGoogle Scholar
Xiong Y-Q, Sun H-C, Zhang W et al (2009) Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res Off J Am Assoc Cancer Res 15:4838–4846. doi:10.1158/1078-0432.CCR-08-2780CrossRefGoogle Scholar
Fattori S, Becherini F, Cianfriglia M et al (2007) Human brain tumors: multidrug-resistance p-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows Arch Int J Pathol 451:81–87. doi:10.1007/s00428-007-0401-zCrossRefGoogle Scholar
Ginguené C, Champier J, Maallem S et al (2010) P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol Zur Switz 20:926–935. doi:10.1111/j.1750-3639.2010.00389.xGoogle Scholar
Tao L-Y, Liang Y-J, Wang F et al (2009) Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 64:961–969. doi:10.1007/s00280-009-0949-1CrossRefPubMedGoogle Scholar
Jovelet C, Bénard J, Forestier F et al (2012) Inhibition of p-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. Eur J Pharm Sci Off J Eur Fed Pharm Sci 46:484–491. doi:10.1016/j.ejps.2012.03.012Google Scholar
Cesca M, Frapolli R, Berndt A et al (2009) The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia N Y N 11:1155–1164CrossRefGoogle Scholar
Alessandri G, Chirivi RG, Castellani P et al (1998) Isolation and characterization of human tumor-derived capillary endothelial cells: role of oncofetal fibronectin. Lab Investig J Tech Methods Pathol 78:127–128Google Scholar
van Beijnum JR, Rousch M, Castermans K et al (2008) Isolation of endothelial cells from fresh tissues. Nat Protoc 3:1085–1091CrossRefPubMedGoogle Scholar
Bonezzi K, Belotti D, North BJ et al (2012) Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia N Y N 14:846–854CrossRefGoogle Scholar